A predator's world? Top analyst sees the 'haves' and the 'haven'ts' diverge as biotech bubbles form — and collapse
We’ve all seen the deluge of cash that’s been pouring into biotech from every angle: VCs, IPOs and follow-ons have generated billions in capital for new and emerging drug developers with ready access to some powerful new tech. But Evercore ISI’s Josh Schimmer is asking where we’re headed from here.
His answer is neither apocalyptic nor universally blissful, but if he’s right — and this is a discussion we’re hearing much, much more about at a time of growing economic and industry uncertainty — we may well be at a crossroads that could affect valuations, M&A and the entire global industry that has formed over the past 5 years.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 65,800+ biopharma pros reading Endpoints daily — and it's free.